Bausch + Lomb Corporation

AI Score

0

Unlock

17.23
-0.14 (-0.81%)
At close: Jan 14, 2025, 3:59 PM
16.77
-2.64%
Pre-market Jan 15, 2025, 05:56 AM EST
undefined%
Bid 16.8
Market Cap 6.07B
Revenue (ttm) -
Net Income (ttm) -
EPS (ttm) -1.02
PE Ratio (ttm) -16.89
Forward PE n/a
Analyst Hold
Ask 17.27
Volume 551,456
Avg. Volume (20D) 507,734
Open 17.37
Previous Close 17.37
Day's Range 16.75 - 17.40
52-Week Range 13.16 - 21.69
Beta undefined

About BLCO

Bausch + Lomb Corporation operates as an eye health company worldwide. It operates through three segments: Vision Care/Consumer Health Care, Ophthalmic Pharmaceuticals, and Surgical. The Vision Care/Consumer Health Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products, over-the-counter eye drops, eye vitamins, and mineral...

Sector Healthcare
IPO Date May 6, 2022
Employees 13,000
Stock Exchange NYSE
Ticker Symbol BLCO

Analyst Forecast

According to 12 analyst ratings, the average rating for BLCO stock is "Hold." The 12-month stock price forecast is $19, which is an increase of 10.30% from the latest price.

Buy 41.67%
Hold 50.00%
Sell 8.33%
Stock Forecasts

Next Earnings Release

Bausch + Lomb Corporation is scheduled to release its earnings on Feb 19, 2025, before market opens.
Analysts project revenue of $1.26B, reflecting a 7.42% YoY growth and earnings per share of 0.24, making a 0.00% YoY.
1 month ago · Source
-12.06%
Bausch + Lomb shares are trading lower after Citig... Unlock content with Pro Subscription
3 months ago · Source
+7.19%
Bausch + Lomb shares are trading higher after the company announced that the FDA approved enVista Envy. Also, a report suggested TPG and Blackstone teamed up to work on a joint bid.